drugset / Trial / NCT03733587

GX-I7 With Cyclophosphamide in Patients With Metastatic or Recurrent Solid Tumors

NCT03733587

Phase 1 Completed 24 enrolled Genexine, Inc.
SequentialOpen-labelTreatment

Summary

This is a Phase 1b study to explore the safety and efficacy of GX-I7 in combination with CPA in patients with metastatic or recurrent solid tumors.

Timeline

Start
2018-10-17
Primary completion
2020-04-02
Completion
2020-05-13

Drugs

EvaluationDrugModalityDoseRoute
Subject NT-I7 Protein / enzyme biologic
Background Cyclophosphamide Other / unclassified

Indications